The Rise and Fall of NMDA Antagonists for Ischemic Stroke

Publisher: Bentham Science Publishers

E-ISSN: 1875-5666|4|2|131-136

ISSN: 1566-5240

Source: Current Molecular Medicine, Vol.4, Iss.2, 2004-03, pp. : 131-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

It has long been accepted that high concentrations of glutamate can destroy neurons,and this is the basis of the theory of excitotoxicity during brain injury such as stroke.Glutamate N-methyl- D-aspartate (NMDA)receptor antagonists such as Selfotel,Aptiganel,Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.The failure of these agents has been attributed to poor studies in animal models and to poorly designed clinical trials.We also speculate that NMDA receptor anatagonism may have hindered endogenous mechanisms for neuronal survival and neuroregeneration.It remains to be proven in human stroke whether NMDA receptor antagonism can be neuroprotective.